Advocacy

FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.

Advocacy > Advocacy Issues

| More

Newsflash

9/26/2018
FORCE joined nearly 100 patient advocacy orgs in expressing concern about allowing Medicare Advantage plans to use step therapy. Read letter...

9/13/2018
We joined in a letter encouraging the House Ways and Means Committee to make the 7.5% medical expense deduction permanent.

9/7/2018
We sent a letter to Senator Collins (R-ME) seeking her leadership on national oral parity legislation

9/5/2018
FORCE signed on to a coalition letter urging the Senate to maintain the allowed medical expense deduction at 7.5% of one's adjusted gross income.

7/25/2018
This week, the House of Representative passed the Palliative Care and Hospice Education and Training Act to improve health professional training in palliative care. Read Bill...

Therapies & Drug Development

FORCE is at the forefront of research and development of therapies for the treatment or prevention of cancers in people affected hereditary cancer. Our organization is active in research advocacy, clinical trial recruitment, drug review and approval, etc. with partners including government agencies, academia and private industry. Our goal is to ensure access to a range of effective treatments for people of every stage and type of hereditary cancer.

Insurance Coverage & Barriers

New Federal Regulations and Proposals May Adversely Affect
High-Risk Cancer Community

October 31, 2018 – With midterm elections looming, the White House and federal agencies recently announced new regulations and proposals—ranging from drug pricing to state ACA waivers and insurance plans to health reimbursement accounts—that will impact health care in the U.S. Some may have negative consequences for our community but expansion of health reimbursement arrangements (HRAs) could provide a silver lining. 

Treatments & Therapies

Federal "Right to Try" Legislation Passes, Signed by President

May 30, 2018 - Federal right-to-try legislation aimed at loosening oversight of access to unapproved drugs for "compassionate use" was signed by President Trump today. The law allows patients with cancer or other serious illnesses to circumvent the Food and Drug Administration (FDA) when requesting access to experimental therapies not yet approved for public use. Congress passed the final right-to-try bill on May 22 after months of negotiation and changes to the legislation.

Treatments & Therapies

Medicare Establishes National Policy for Coverage of Tumor Testing

The Centers for Medicare and Medicaid Services (CMS) recently finalized a National Coverage Determination (NCD) to provide Medicare beneficiaries with coverage of FDA-approved or -cleared tests that help identify the best treatment options for an individual's disease. These tests, also known as companion diagnostics, examine a person’s tumor or blood to determine which targeted medications may be most effective for treating their cancer. The new policy applies only to patients with advanced cancer.

Insurance Coverage & Barriers

FORCE Supports Chemotherapy Parity Initiatives

Oral chemotherapy is becoming standard-of-care for many types of cancer and accounts for about a third of the oncology development pipeline. Importantly, many oral anti-cancer medications do not have IV or injected alternatives. PARP inhibitors, which hold great promise for treating BRCA-related cancers, are just one example. For this reason, these medications must be as affordable as their IV counterparts. FORCE is supporting the Cancer Drug Coverage Parity Act, a federal legislative initiative which strives to create equal insurance coverage cancer treatments, regardless of how they are administered.

Treatments & Therapies

Cancer Research Funding Preserved

Federal funding for cancer research has led to significant advances in cancer prevention, detection, diagnosis, treatment, and quality of life for patients. More than 14 million U.S. cancer survivors are alive today, largely because of the nation’s commitment to cancer research. The main sources of U.S. cancer research funding are the National Institutes of Health (NIH), which includes the National Cancer Institute (NCI), and the Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP). FORCE was involved in recent efforts to preserve or increase funding for these crucial programs. 

Treatments & Therapies

ICER Review of PARP Inhibitors for Ovarian Cancer

In July 2017, the Institute for Clinical and Economic Review (ICER) released a draft evidence report titled, “Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness and Value.” FORCE expressed significant concerns about the report's conclusions via written comments and testified at the Midwest CEPAC meeting on September 14, 2017. ICER released its final report later that month. Despite our efforts and those of many others, the final report does not reflect the value of PARP inhibitors to the broader ovarian cancer community, or to the hereditary cancer community we serve. 

Treatments & Therapies

Cancer Moonshot

In his final State of the Union address in 2016, President Obama tasked Vice President Biden with heading up a new national effort, the Cancer Moonshot. The ultimate goal of Moonshot is to double the rate of progress—to make a decade's worth of advances in cancer prevention, diagnosis, treatment, and care in five years—to ultimately end cancer as we know it. FORCE is proud to be engaged in the Moonshot initiative via the ABOUT Network, the only cancer-focused patient-powered research network in PCORnet. 

Search Policy Issues by Keyword

FORCE:Facing Our Risk of Cancer Empowered